161 related articles for article (PubMed ID: 10649731)
1. Androgens for the treatment of anemia in peritoneal dialysis patients.
Navarro JF; Mora-Fernández C; Rivero A; Macía M; Gallego E; Chahin J; Méndez ML; García J
Adv Perit Dial; 1998; 14():232-5. PubMed ID: 10649731
[TBL] [Abstract][Full Text] [Related]
2. Randomized prospective comparison between erythropoietin and androgens in CAPD patients.
Navarro JF; Mora C; Macía M; García J
Kidney Int; 2002 Apr; 61(4):1537-44. PubMed ID: 11918762
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment of refractory anemia with a combination regimen containing recombinant human erythropoietin, low-dose methylprednisolone and nandrolone.
Tsiara SN; Chaidos A; Gouva M; Christou L; Panteli K; Kapsali E; Bourantas KL
J Exp Clin Cancer Res; 2004 Mar; 23(1):47-52. PubMed ID: 15149150
[TBL] [Abstract][Full Text] [Related]
4. Use of nandrolone decanoate as an adjuvant for erythropoietin dose reduction in treating anemia in patients on hemodialysis.
Sheashaa H; Abdel-Razek W; El-Husseini A; Selim A; Hassan N; Abbas T; El-Askalani H; Sobh M
Nephron Clin Pract; 2005; 99(4):c102-6. PubMed ID: 15703460
[TBL] [Abstract][Full Text] [Related]
5. Erythropoietin requirements: a comparative multicenter study between peritoneal dialysis and hemodialysis.
Coronel F; Herrero JA; Montenegro J; Fernandez C; Gandara A; Conesa J; Rivera MT; Torrente J; Portolés J; Gomez-Martino JR
J Nephrol; 2003; 16(5):697-702. PubMed ID: 14733416
[TBL] [Abstract][Full Text] [Related]
6. A controlled trial of recombinant human erythropoietin and nandrolone decanoate in the treatment of anemia in patients on chronic hemodialysis.
Berns JS; Rudnick MR; Cohen RM
Clin Nephrol; 1992 May; 37(5):264-7. PubMed ID: 1606777
[TBL] [Abstract][Full Text] [Related]
7. Evolution of serum erythropoietin after androgen administration to hemodialysis patients: a prospective study.
Teruel JL; Marcén R; Navarro JF; Villafruela JJ; Fernández Lucas M; Liaño F; Ortuño J
Nephron; 1995; 70(3):282-6. PubMed ID: 7477614
[TBL] [Abstract][Full Text] [Related]
8. Androgens potentiate the effects of erythropoietin in the treatment of anemia of end-stage renal disease.
Ballal SH; Domoto DT; Polack DC; Marciulonis P; Martin KJ
Am J Kidney Dis; 1991 Jan; 17(1):29-33. PubMed ID: 1986567
[TBL] [Abstract][Full Text] [Related]
9. Androgen therapy for anaemia of chronic renal failure. Indications in the erythropoietin era.
Teruel JL; Aguilera A; Marcen R; Navarro Antolin J; Garcia Otero G; Ortuño J
Scand J Urol Nephrol; 1996 Oct; 30(5):403-8. PubMed ID: 8936631
[TBL] [Abstract][Full Text] [Related]
10. The effects of nandrolone decanoate on nutritional parameters in hemodialysis patients.
Barton Pai A; Chretien C; Lau AH
Clin Nephrol; 2002 Jul; 58(1):38-46. PubMed ID: 12141405
[TBL] [Abstract][Full Text] [Related]
11. A 6-month study of low-dose recombinant human erythropoietin alone and in combination with androgens for the treatment of anemia in chronic hemodialysis patients.
Gaughan WJ; Liss KA; Dunn SR; Mangold AM; Buhsmer JP; Michael B; Burke JF
Am J Kidney Dis; 1997 Oct; 30(4):495-500. PubMed ID: 9328363
[TBL] [Abstract][Full Text] [Related]
12. Effects of angiotensin-converting enzyme inhibitors on anemia and erythropoietin requirements in peritoneal dialysis patients.
Navarro JF; Macía ML; Mora-Fernández C; Gallego E; Chahin J; Méndez ML; del Castillo N; Rivero A; García J
Adv Perit Dial; 1997; 13():257-9. PubMed ID: 9360694
[TBL] [Abstract][Full Text] [Related]
13. Nutritional effect of nandrolone decanoate in predialysis patients with chronic kidney disease.
Eiam-Ong S; Buranaosot S; Eiam-Ong S; Wathanavaha A; Pansin P
J Ren Nutr; 2007 May; 17(3):173-8. PubMed ID: 17462549
[TBL] [Abstract][Full Text] [Related]
14. Nandrolone decanoate reduces serum lipoprotein(a) concentrations in hemodialysis patients.
Teruel JL; Lasuncion MA; Rivera M; Aguilera A; Ortega H; Tato A; Marcen R; Ortuño J
Am J Kidney Dis; 1997 Apr; 29(4):569-75. PubMed ID: 9100047
[TBL] [Abstract][Full Text] [Related]
15. Administration of exogenous erythropoietin beta affects lipid peroxidation and serum paraoxonase-1 activity and concentration in predialysis patients with chronic renal disease and anaemia.
Marsillach J; Martínez-Vea A; Marcas L; Mackness B; Mackness M; Ferré N; Joven J; Camps J
Clin Exp Pharmacol Physiol; 2007 Apr; 34(4):347-9. PubMed ID: 17324148
[TBL] [Abstract][Full Text] [Related]
16. Nandrolone decanoate for the treatment of erythropoietin refractory anemia: a case series.
Chawla B; Iqbal FM; Chawla MS
Compr Ther; 2009; 35(3-4):199-203. PubMed ID: 20043618
[TBL] [Abstract][Full Text] [Related]
17. Androgens for the anaemia of chronic kidney disease in adults.
Yang Q; Abudou M; Xie XS; Wu T
Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD006881. PubMed ID: 25300168
[TBL] [Abstract][Full Text] [Related]
18. Lymphocyte 5'-nucleotidase and aminopeptidase N activity in patients on maintenance hemodialysis treated with human recombinant erythropoietin and 1-alpha-D3.
Stefanovic V; Mitić-Zlatkovic M; Radivojevic J; Vlahovic P
Ren Fail; 2005; 27(3):283-8. PubMed ID: 15957544
[TBL] [Abstract][Full Text] [Related]
19. Relationship between residual renal function, inflammation, and anemia in peritoneal dialysis.
Pérez-Flores I; Coronel F; Cigarrán S; Herrero JA; Calvo N
Adv Perit Dial; 2007; 23():140-3. PubMed ID: 17886621
[TBL] [Abstract][Full Text] [Related]
20. A comparison of androgens for anemia in patients on hemodialysis.
Neff MS; Goldberg J; Slifkin RF; Eiser AR; Calamia V; Kaplan M; Baez A; Gupta S; Mattoo N
N Engl J Med; 1981 Apr; 304(15):871-5. PubMed ID: 7010161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
